Unknown

Dataset Information

Statin tolerability: In defence of placebo-controlled trials.


ABSTRACT:

Background

Statin intolerance is a barrier to effective lipid-lowering treatment. A significant number of patients stop prescribed statins, or can take only a reduced dose, because of adverse events attributed to the statin, and are then considered statin-intolerant.

Methods

Examination of differences between statin and placebo in withdrawal rates due to adverse events - a good measure of tolerability - in statin cardiovascular outcome trials in patients with advanced disease and complex medical histories, who may be more vulnerable to adverse effects. The arguments commonly used to dismiss safety and tolerability data in statin clinical trials are examined.

Results

Rates of withdrawal due to adverse events in trials in patients with advanced disease and complex medic

SUBMITTER: Tobert JA 

PROVIDER: S-EPMC4847124 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature